Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States

Annals of Surgical Oncology

Volumn 20, Issue 2, 2013, Pages 362-370

  Sherman, Karen L ^a   Merkow, Ryan P ^a,b   Bilimoria, Karl Y ^a   Wang, C Edward ^a   Mulcahy, Mary F ^a   Benson, Al B ^a   Bentrem, David J ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CARDIA; DATA BASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH ADENOCARCINOMA; UNITED STATES;

ADENOCARCINOMA; AGED; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS; SURVIVAL RATE; UNITED STATES;

EID: 84878871694     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2552-7     Document Type: Article

References (33)

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354-62.
2. Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20:633-49.
3. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11:1441-7.
4. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-30.
5. Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol. 2002;9:278-86.
6. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774-80.
7. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
8. Van Cutsem E, Dicato M, Arber N, et al. The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. Ann Oncol. 2006;17(Suppl 6):13-8.
9. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-20.
10. Cunningham D, Allen WH, Stenning SP, et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 2005;23(16S, Part I of II, June 1 Supplement):4001.
11. Macdonald JS. Gastric cancer: Nagoya is not New York. J Clin Oncol. 2011;29:4348-50.
12. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683-90.
13. World Health Organization. International classification of disease for oncology. 2nd ed. Geneva: World Health Organization; 1990.
14. World Health Organization. International classification of disease for oncology. 3rd ed. Geneva: World Helath Organization; 2000.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-9.
17. Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.
18. Commission on Cancer. Cancer program accreditation. http://www.facs.org/ cancer/coc/whatis.html.
19. Commission on Cancer. Facility oncology registry data standards. Chicago: Commission on Cancer; 2004.
20. National Comprehensive Cancer Network Guidelines in Oncology. Gastric cancer. http://www.nccn.org.
21. Balas EA, Boren SA. Managing clinical knowledge for health care improvement. In: Bemmel J, Mccray AT, editors. Yearbook of medical informatics, 2000: patient-centered systems. Stuttgart: Schattauer Verlagsgesellschaft; 2000. p. 65-70.
22. Coburn NG, Guller U, Baxter NN, et al. Adjuvant therapy for resected gastric cancer - rapid, yet incomplete adoption following results of Intergroup 0116 Trial. Int J Radiat Oncol Biol Phys. 2008;70:1073-80.
23. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173-80.
24. Bilimoria KY, Bentrem DJ, Linn JG, et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery. 2007;142:906-13.
25. Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2008;15:1566-76.
26. Merkow RP, Bilimoria KY, McCarter MD, Chow WB, Ko CY, Bentrem DJ. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals. Ann Surg Oncol. 2012;19:357-64.
27. Steyerberg EW, Neville B, Weeks JC, Earle CC. Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2007;25:2389-96.
28. Hynes DM, Tarlov E, Durazo-Arvizu R, et al. Surgery and adjuvant chemotherapy use among veterans with colon cancer: insights from a California study. J Clin Oncol. 2010;28:2571-6.
29. Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer. 1997;80:2333-41.
30. Dobie SA, Warren JL, Matthews B, Schwartz D, Baldwin LM, Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer. 2008;112:789-99.
31. Dudeja V, Habermann EB, Zhong W, et al. Guideline recommended gastric cancer care in the elderly: insights into the applicability of cancer trials to real world. Ann Surg Oncol. 2011;18:26-33.
32. Al-Refaie WB, Tseng JF, Gay G, et al. The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer. 2008;113:461-9.
33. Dudeja V, Gay G, Habermann EB, et al. Do hospital attributes predict guideline-recommended gastric cancer care in the United States? Ann Surg Oncol. 2012;19:365-72.